摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(1-azabicyclo[2.2.1]heptan-4-yl)acetamide

中文名称
——
中文别名
——
英文名称
N-(1-azabicyclo[2.2.1]heptan-4-yl)acetamide
英文别名
——
N-(1-azabicyclo[2.2.1]heptan-4-yl)acetamide化学式
CAS
——
化学式
C8H14N2O
mdl
——
分子量
154.21
InChiKey
UQWGHVFUYAQPSP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.3
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.88
  • 拓扑面积:
    32.3
  • 氢给体数:
    1
  • 氢受体数:
    2

文献信息

  • [EN] CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS<br/>[FR] DÉRIVÉS D'IMIDAZOLE CONDENSÉS, SUBSTITUÉS PAR DES GROUPES HYDROXY TERTIAIRES, UTILISÉS COMME INHIBITEURS DE PI3K-GAMMA
    申请人:INCYTE CORP
    公开号:WO2019079469A1
    公开(公告)日:2019-04-25
    This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-y which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    这种应用涉及到式(I)的化合物或其药用可接受的盐,这些化合物是PI3K-y的抑制剂,对于治疗自身免疫疾病、癌症、心血管疾病和神经退行性疾病等疾病是有用的。
  • RING-FUSED HETEROCYCLIC COMPOUND
    申请人:Kyowa Hakko Kirin Co., Ltd.
    公开号:US20150284384A1
    公开(公告)日:2015-10-08
    The ring-fused heterocyclic compound or a pharmaceutically acceptable salt thereof according to the present invention has a T-type calcium channel regulatory effect, and is useful, for example, as a medicament for treating and/or preventing pruritus. The present invention provides a ring-fused heterocyclic compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof and the like which has a T-type calcium channel regulatory effect and is useful as a therapeutic and/or preventive agent for pruritus, and the like. [wherein, R 1 represents optionally substituted lower alkyl and the like, R 2 represents optionally substituted lower alkyl and the like, R 3 represents the formula (II): (wherein, n represents 0 or 1, R 3a represents a hydrogen atom and the like, R 3b represents a hydrogen atom and the like, and R 3c represents a hydrogen atom and the like) and the like, Q represents a hydrogen atom and the like, and W 1 represents a nitrogen atom and the like, W 2 represents a nitrogen atom and the like]
    根据本发明,环融合杂环化合物或其药学上可接受的盐具有T型钙通道调节作用,例如,可用作治疗和/或预防瘙痒的药物。本发明提供了由以下一般式(I)或其药学上可接受的盐等表示的环融合杂环化合物,具有T型钙通道调节作用,可用作治疗和/或预防瘙痒等疾病的治疗和/或预防剂。其中,R1代表可选取代的低碳基等,R2代表可选取代的低碳基等,R3代表公式(II):(其中,n代表0或1,R3a代表氢原子等,R3b代表氢原子等,R3c代表氢原子等)等,Q代表氢原子等,W1代表氮原子等,W2代表氮原子等。
  • Tertiary alcohols as PI3K-γ inhibitors
    申请人:Incyte Corporation
    公开号:US11225486B2
    公开(公告)日:2022-01-18
    This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    本申请涉及式 (I) 化合物: 或其药学上可接受的盐,它们是 PI3K-γ 的抑制剂,可用于治疗自身免疫性疾病、癌症、心血管疾病和神经退行性疾病等疾病。
  • CONDENSED RING HETEROCYCLIC COMPOUND
    申请人:Kyowa Hakko Kirin Co., Ltd.
    公开号:EP2881394B1
    公开(公告)日:2018-03-21
  • CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS
    申请人:Incyte Corporation
    公开号:EP3697789B1
    公开(公告)日:2021-09-29
查看更多